NCT06681298View on ClinicalTrials.gov

A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2029

Study Completion Date

May 1, 2029

Conditions

Adenocarcinoma of the Esophagogastric JunctionPerioperative Period

Interventions

DRUG

The experimental group received Nivolumab

Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.

Trial Locations (1)

710032

The First Affiliated Hospital of the Air Force Medical University, Xi'an

All Listed Sponsors

lead

xiaohua li

OTHER